Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. MGC Pharmaceuticals Limited
  6. Summary
    MXC   AU000000MXC6

MGC PHARMACEUTICALS LIMITED

(MXC)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/15
0.054 AUD   -1.82%
10/07MGC PHARMACEUTICALS : Bags $3 Million Purchase Order For COVID-19 Treatment Drug
MT
10/06MGC Pharmaceuticals Limited Receives Purchase Order
CI
10/06Brexit Risks, Rising Prices Seen Weighing on Sterling
DJ
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
0.055 0.054 0.053 0.055 0.054 Last
7946368 3411363 2393731 1185663 5163704 Volume
-5.17% -1.82% -1.85% +3.77% -1.82% Change
Estimated financial data (e)
Sales 2022 20,2 M 15,0 M 15,0 M
Net income 2022 -7,42 M -5,51 M -5,51 M
Net Debt 2022 7,90 M 5,86 M 5,86 M
P/E ratio 2022 -19,3x
Yield 2022 -
Sales 2023 40,3 M 29,9 M 29,9 M
Net income 2023 - - -
Net Debt 2023 8,50 M 6,31 M 6,31 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 130 M 96,4 M 96,3 M
EV / Sales 2022 6,82x
EV / Sales 2023 3,43x
Nbr of Employees -
Free-Float 93,7%
More Financials
Company
MGC Pharmaceuticals Limited is an Australia-based biopharma company. The Company is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The CompanyÔÇÖs Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Ratings of MGC Pharmaceuticals Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MGC PHARMACEUTICALS LIMITED
10/07MGC PHARMACEUTICALS : Bags $3 Million Purchase Order For COVID-19 Treatment Drug
MT
10/06MGC Pharmaceuticals Limited Receives Purchase Order
CI
10/06Brexit Risks, Rising Prices Seen Weighing on Sterling
DJ
10/06FTSE 100 Falls on Fears Over Energy Prices; Tesco Gains
DJ
09/30MGC PHARMACEUTICALS : Receives First Supply Order for CimetrA
MT
09/30MGC Pharmaceuticals Limited Auditor Raises 'Going Concern' Doubt
CI
09/29AMC Holdings Orders First 1,000 Units of CimetraÖ to Fast-Track USA Sales and Research ..
CI
09/15MGC Pharmaceuticals Ltd Provides Material Update on Its Proprietary Nutraceutical Food ..
CI
09/13MGC PHARMACEUTICALS' : Refractory Epilepsy Drug Receives UK Import Permit; Shares Jump 8%
MT
09/13MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil
CI
09/02MGC PHARMACEUTICALS : Surges 11% After Securing Indian Import Permit for COVID-19 Phytomed..
MT
09/01MGC PHARMACEUTICALS : Earnings Flash (MXC.L) MGC PHARMACEUTICALS Reports FY21 Revenue $3M
MT
09/01MGC PHARMACEUTICALS : Earnings Flash (MXC.L) MGC PHARMACEUTICALS Posts FY21 Loss $-0.73
MT
08/31MGC Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2..
CI
08/31MGC PHARMACEUTICALS : To Issue 45,367,806 Shares To AMC
MT
More news
News in other languages on MGC PHARMACEUTICALS LIMITED
10/07MGC Pharmaceuticals obtient un bon de commande de 3 millions de dollars pour un médicam..
09/30MGC Pharmaceuticals reçoit la première commande de fourniture de CimetrA
09/13Le médicament contre l'épilepsie réfractaire de MGC Pharmaceuticals obtient un permis d..
09/02MGC Pharmaceuticals bondit de 11% après avoir obtenu un permis d'importation indien pou..
09/01Earnings Flash (MXC.L) MGC PHARMACEUTICALS annonce un revenu de 3 millions de dollars p..
More news
Chart MGC PHARMACEUTICALS LIMITED
Duration : Period :
MGC Pharmaceuticals Limited Technical Analysis Chart | MXC | AU000000MXC6 | MarketScreener
Technical analysis trends MGC PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,05 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Roby Reuven Zomer Chief Executive Officer, MD & Director
Brett Anthony Mitchell Executive Chairman
Amir Polak Chief Technology Officer
Stephen B. Parker Senior Independent Director
Evan Hayes Independent Non-Executive Director
Sector and Competitors